166 related articles for article (PubMed ID: 18585847)
1. Editorial comment on: Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients.
van der Poel HG
Eur Urol; 2009 May; 55(5):1133-4. PubMed ID: 18585847
[No Abstract] [Full Text] [Related]
2. Editorial comment on: Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients.
Berney DM
Eur Urol; 2009 May; 55(5):1134. PubMed ID: 18585844
[No Abstract] [Full Text] [Related]
3. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients.
Gupta A; Lotan Y; Ashfaq R; Roehrborn CG; Raj GV; Aragaki CC; Montorsi F; Shariat SF
Eur Urol; 2009 May; 55(5):1124-33. PubMed ID: 18585843
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activation inhibitor-1 improves the predictive accuracy of prostate cancer nomograms.
Shariat SF; Park S; Trinh QD; Roehrborn CG; Slawin KM; Karakiewicz PI
J Urol; 2007 Oct; 178(4 Pt 1):1229-36; discussion 1236-7. PubMed ID: 17698116
[TBL] [Abstract][Full Text] [Related]
5. Editorial Comment to Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases.
Viney R
Int J Urol; 2010 Nov; 17(11):922-3. PubMed ID: 20969639
[No Abstract] [Full Text] [Related]
6. Editorial comment on: systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy.
Trpkov K
Eur Urol; 2007 Sep; 52(3):743-4. PubMed ID: 17350751
[No Abstract] [Full Text] [Related]
7. Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.
Milanese G; Dellabella M; Fazioli F; Pierpaoli E; Polito M; Siednius N; Montironi R; Blasi F; Muzzonigro G
J Urol; 2009 Mar; 181(3):1393-400. PubMed ID: 19157433
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment prostate-specific antigen velocity and the risk of death from prostate cancer in the individual with low-risk prostate cancer.
D'Amico AV; Chen MH
J Clin Oncol; 2009 Aug; 27(22):3575-6. PubMed ID: 19506151
[No Abstract] [Full Text] [Related]
9. Editorial comment on: ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer.
Cooper C
Eur Urol; 2008 Nov; 54(5):1107-8. PubMed ID: 18061340
[No Abstract] [Full Text] [Related]
10. Editorial comment on: ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer.
Valentini A; Bernardini S
Eur Urol; 2008 Nov; 54(5):1106-7. PubMed ID: 18061338
[No Abstract] [Full Text] [Related]
11. Editorial comment on: systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy.
Greene DR
Eur Urol; 2007 Sep; 52(3):744-5. PubMed ID: 17350749
[No Abstract] [Full Text] [Related]
12. Editorial comment.
Moul JW
Urology; 2010 Feb; 75(2):445-6; author reply 446. PubMed ID: 20152507
[No Abstract] [Full Text] [Related]
13. Editorial comment.
Slawin KM
Urology; 2010 Feb; 75(2):444-5; author reply 445. PubMed ID: 20152505
[No Abstract] [Full Text] [Related]
14. Editorial comment on: Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy.
Hakenberg OW
Eur Urol; 2009 Feb; 55(2):421. PubMed ID: 19027224
[No Abstract] [Full Text] [Related]
15. Editorial comment.
Naselli A
J Urol; 2009 Nov; 182(5):2256. PubMed ID: 19758664
[No Abstract] [Full Text] [Related]
16. Editorial comment.
Makarov DV
J Urol; 2009 Nov; 182(5):2255-6. PubMed ID: 19758643
[No Abstract] [Full Text] [Related]
17. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer.
Thomas C; Wiesner C; Melchior SW; Schmidt F; Gillitzer R; Thüroff JW; Pfitzenmaier J
BJU Int; 2009 Jul; 104(1):29-34. PubMed ID: 19154451
[TBL] [Abstract][Full Text] [Related]
18. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers.
Shariat SF; Karam JA; Walz J; Roehrborn CG; Montorsi F; Margulis V; Saad F; Slawin KM; Karakiewicz PI
Clin Cancer Res; 2008 Jun; 14(12):3785-91. PubMed ID: 18559597
[TBL] [Abstract][Full Text] [Related]
19. Soluble urokinase plasminogen activator receptor as a prognostic marker in men participating in prostate cancer screening.
Kjellman A; Akre O; Gustafsson O; Høyer-Hansen G; Lilja H; Norming U; Piironen T; Törnblom M
J Intern Med; 2011 Mar; 269(3):299-305. PubMed ID: 21138491
[TBL] [Abstract][Full Text] [Related]
20. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
